Conor Medsystems was developed drug-eluting stent, which could capture a significant share of the $ 5 billion global market. Chief Executive Officer Frank Litvack, exploring alternative sources of funding for testing the device. "Hide
by Linda A. Cyr, Bijan Salehizadeh, Robert F. Higgins, Donald N. Sull Source: Harvard Business School 29 pages. Publication Date: April 28, 2004. Prod. #: 804180-PDF-ENG
Related Case Solutions & Analyses:
NTT DoCoMo (TM): Value Innovation at DoCoMo
Butler Shine Stern & Partners
American National Red Cross (B)
ConAgra Inc.: Across the Food Chain
The Upside of Messiness: Clumsy Solutions for Wicked Problems
Balanced Workplace Flexibility: Avoiding the Traps
Negotiating with the Cuban Sugar Industry (A): No Way Out?
HgCapital and the Visma Transaction (A)
Managing Knowledge at Booz-Allen and Hamilton: Knowledge On-Line and Off (A)
The House that Branson Built: From Counter-culture to Corporate Culture
